Skip to navigation Skip to main content

ConfirmMDx, a new epigenetic assay to prevent repeat biopsies

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

ConfirmMDx, an epigenetic assay developed by MDxHealth, uses an epigenetic field effect (“halo”) to determine the risk of cancerization at a DNA level. The innovative test can help to single out men without a risk of prostate cancer from undergoing unnecessary biopsies as well as identify patients who need treatment.

Click here to watch E. David Crawford, MD, talk about his experience with MDx.

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Next hm-slideshow in Slides